Aviado · Research
Longevity Daily
Sunday, October 25, 2026
Listen
Today's Brief
History was made this week as Life Biosciences — co-founded by Harvard's David Sinclair — reported the first human results from an age reversal gene therapy, with two of three glaucoma patients showing measurable improvement. A Cell Metabolism study adds another reason to exercise: bone's ability to sense mechanical force appears to regulate whole-body aging and extended mouse lifespan by ~9%. Columbia researchers separately identify a rare FN1 gene mutation that appears to shield against Alzheimer's by controlling fibronectin buildup — opening a fresh treatment angle. Aviado also breaks down the clinical case for nicotinamide riboside as one of the most evidence-backed tools in the longevity supplement stack.
10 stories3 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
A Rare Gene Mutation Appears to Shield Against Alzheimer's — And Points to a New Treatment Target
Columbia University researchers have identified a rare FN1 gene mutation that appears to protect against Alzheimer's disease by keeping fibronectin — a protein that accumulates abnormally in Alzheimer's-affected brains — under tight control. Zebrafish engineered with the mutation showed dramatically lower fibronectin buildup compared to controls, pointing to a potential new therapeutic strategy. For those carrying the high-risk APOE4 variant, this opens a fresh avenue: targeting fibronectin accumulation rather than amyloid alone.
Read more →Common Supplement Clears 'Chemo Brain' in Breast Cancer Survivors, UCLA Trial Finds
In a UCLA clinical trial, breast cancer survivors who took a common dietary supplement for eight weeks reported significantly sharper thinking — offering one of the first controlled interventions for post-chemotherapy cognitive impairment, or 'chemo brain.' The mechanism likely involves reducing neuroinflammation, a known driver of cognitive fog following cancer treatment. Click through for the specific supplement name — it may already be on your shelf.
Read more →Neuriva Is Everywhere — But Does the Science Actually Back It?
Neuriva is one of America's best-selling brain supplements, but a Pharmacy Times clinical review finds its key ingredients — phosphatidylserine and coffee cherry extract — are supported by limited, mixed, and often industry-funded evidence. Most supporting studies are small, short-term, or fail to replicate outside of manufacturer-commissioned trials. If you're spending on Neuriva for cognitive protection, this analysis suggests the evidence doesn't yet justify the price tag.
Read more →Supplements & Compounds
How Nicotinamide Riboside Boosts NAD+ to Power Cellular Energy Systems
NAD+ powers your cells' DNA repair, energy production, and mitochondrial function — and levels drop substantially with age, accelerating cognitive decline, metabolic dysfunction, and cardiovascular risk. Clinical trials consistently show that 500–2,000mg daily of nicotinamide riboside (NR) raises NAD+ by 2–3 fold within weeks, with downstream improvements in cognitive function, muscle mitochondrial capacity, and cardiovascular biomarkers. Unlike precursors that cause flushing or have poor absorption, NR converts efficiently through dedicated cellular pathways, making it one of the most practical and well-evidenced entries in the longevity supplement toolkit.
Read the full Aviado analysis →Add Macular Degeneration to the List: Metformin Linked to Reduced AMD Risk
A new analysis finds that metformin — the diabetes drug increasingly used off-label as a geroprotector — is associated with significantly reduced risk of developing age-related macular degeneration (AMD). Researchers link the effect to metformin's well-documented anti-inflammatory and antioxidant properties, which target pathways shared by AMD and broader aging biology. For those already considering metformin for longevity, this adds a meaningful eye-health benefit to the growing evidence base.
Read more →Research & Papers
World First: David Sinclair's Age Reversal Gene Therapy Reports Its First Human Results
Life Biosciences — co-founded by Harvard's David Sinclair — has released the first human results from ER-100, a gene therapy that uses three Yamanaka factors (OSK) to biologically reset aging cells in the eye. Administered to three glaucoma patients at a low dose, the therapy was well tolerated, and two of the three showed measurable improvement on visual field testing. This is a landmark moment: the first age reversal gene therapy ever given to humans has now reported real data, and the early signal is cautiously encouraging. Sample size is tiny (n=3) and results will need replication in larger trials, but the field — and your longevity watchlist — just leveled up.
Read more →Your Bones Know When You Exercise — And It May Control How Fast You Age
A study in Cell Metabolism reveals that bone is far more than structural support: osteocytes actively sense mechanical force, and when that sensing is impaired, whole-body aging accelerates across multiple systems. In mice, targeted tibial loading at 20–24 months of age extended lifespan by 9.4% (about 79.5 days) and reversed immune aging in bone marrow. Researchers also identified a novel anti-aging factor called PEDF that responds to mechanical stimulation and correlates with healthy aging in humans — adding mechanistic weight to the case for bone-loading exercise as a longevity tool.
Read more →Lifestyle & Nutrition
Resistance Training Changed Cancer Survivors' Blood So Much It Suppressed Tumor Growth in the Lab
A January 2026 randomized trial found that blood serum collected from breast cancer survivors after 12 weeks of resistance training or HIIT suppressed breast cancer cell growth in laboratory testing — suggesting exercise reshapes the body's internal biological environment, not just its fitness markers. For cancer survivors and prevention-focused individuals alike, this adds compelling mechanistic evidence to the case for structured strength and high-intensity training. The finding raises a follow-up worth watching: which training modality produced the stronger anti-tumor effect?
Read more →Industry & Policy
Immorta Bio's Senolytic Peptide Eyes Human Trials to Destroy Zombie Cells
Longevity biotech Immorta Bio is preparing to enter human trials with a nine-amino-acid senolytic peptide designed to selectively eliminate senescent ('zombie') cells — a hallmark of aging linked to chronic inflammation and age-related disease. The company expects initial human evaluation before year-end 2026, making this one of the first senolytic immunotherapy candidates to approach clinical testing. Senolytics have shown dramatic results in preclinical models; whether a peptide-based approach clears early safety trials will be closely watched across the longevity field.
Read more →FDA Finalizes Supplement Safety Rules — Raising the Bar for New Ingredients
The FDA has finalized its long-awaited guidance on New Dietary Ingredients (NDIs), establishing clearer requirements for how companies must document identity, safety history, and safety rationale for novel supplement ingredients before bringing them to market. The guidance closes out three sections that sat in draft form since 2016 — a decade-long wait that frustrated regulators and industry alike. For consumers, this raises the accountability floor for novel formulations; for manufacturers, it means new ingredients now face meaningfully more rigorous pre-market scrutiny.
Read more →